Literature DB >> 11290480

Europium fluorescence to visualize N-butyl 2-cyanoacrylate in embolized vessels of an arteriovenous malformation swine model.

W J Calvo1, B B Lieber, L N Hopkins, A K Wakhloo.   

Abstract

BACKGROUND AND
PURPOSE: Standard tissue staining using the lipid dye Oil-Red-O has been previously applied to stain vessel specimens, which were embolized with a mixture of n-butyl 2-cyanoacrylate (NBCA) and oil (Lipiodol). That technique, however, results in nonspecific and nonquantitative staining that does not provide the necessary differentiation between NBCA and Lipiodol. We present an innovative staining procedure that quantifies NBCA within treated tissues.
METHODS: An arteriovenous malformation (AVM) model in swine was used to evaluate the polymerization characteristics of various ratios of Lipiodol/NBCA/glacial acetic acid (GAA) mixtures. To determine the depth of NBCA penetration within the AVM model and to characterize the polymerization patterns of various mixtures within the vessel, histologic cross- and longitudinal sections were prepared for microscopy. These paraffin-embedded tissue sections were stained with a europium aryl-beta-diketone complex (TEC) to improve differentiation between NBCA and Lipiodol. Quantification of NBCA and Lipiodol within the lumen of rete cross-sections was accomplished using image analysis software to determine percent luminal area occluded by embolization.
RESULTS: Upon application of TEC, intense europium fluorescence was seen when the tissue samples were excited by low-power UV light (excitation at 365 nm; emission at 614 nm). The area of europium intensity within the lumen corresponded to NBCA concentration, and addition of GAA aided the NBCA distribution throughout the lumen without affecting fluorescence intensity. It was seen that NBCA could be easily differentiated from Lipiodol and that quantification could be readily performed on these sections because of the improved differentiation. For the case of a 50:50 (vol. %) mixture with an added 20 microL of GAA, luminal area distribution of Lipiodol, NBCA, and blood products was 42.6 +/- 3.5%, 33.8 +/- 5.7%, and 23.7 +/-2.7%, respectively.
CONCLUSION: The rare earth metal europium, when added as a fluorescent chelate compound to histologic tissue sections, allowed for differentiation between NBCA and Lipiodol with good detail. These results have facilitated further characterization of NBCA polymerization for the use of AVM embolization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290480      PMCID: PMC7976015     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Revascularization of brain arteriovenous malformations after embolization with bucrylate.

Authors:  D Fournier; K Terbrugge; G Rodesch; P Lasjaunias
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  The use of peroxidase-mediated deposition of biotin-tyramide in combination with time-resolved fluorescence imaging of europium chelate label in immunohistochemistry and in situ hybridization.

Authors:  R R de Haas; N P Verwoerd; M P van der Corput; R P van Gijlswijk; H Siitari; H J Tanke
Journal:  J Histochem Cytochem       Date:  1996-10       Impact factor: 2.479

3.  Detection of cyanoacrylate tissue adhesives in histological sections.

Authors:  K A Galil; I D Schofield; G Z Wright
Journal:  J Biomed Mater Res       Date:  1984 Jul-Aug

4.  Staining procedure to aid in assessment of bucrylate histotoxicity in tissue sections.

Authors:  M J Lundie; D Ellyatt; J C Kaufmann; H V Vinters
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

5.  Time-resolved delayed luminescence image microscopy using an europium ion chelate complex.

Authors:  G Marriott; M Heidecker; E P Diamandis; Y Yan-Marriott
Journal:  Biophys J       Date:  1994-09       Impact factor: 4.033

6.  Use of genetically engineered lipid-tagged antibody to generate functional europium chelate-loaded liposomes. Application in fluoroimmunoassay.

Authors:  M L Laukkanen; A Orellana; K Keinänen
Journal:  J Immunol Methods       Date:  1995-09-11       Impact factor: 2.303

7.  Microcatheter adhesion of cyanoacrylates: comparison of normal butyl cyanoacrylate to 2-hexyl cyanoacrylate.

Authors:  J D Barr; E J Hoffman; B R Davis; K A Edgar; C R Jacobs
Journal:  J Vasc Interv Radiol       Date:  1999-02       Impact factor: 3.464

8.  Modification of a previously described arteriovenous malformation model in the swine: endovascular and combined surgical/endovascular construction and hemodynamics.

Authors:  R Siekmann; A K Wakhloo; B B Lieber; M J Gounis; A A Divani; L N Hopkins
Journal:  AJNR Am J Neuroradiol       Date:  2000-10       Impact factor: 3.825

9.  A novel approach to flow quantification in brain arteriovenous malformations prior to enbucrilate embolization: use of insoluble contrast (Ethiodol droplet) angiography.

Authors:  A K Wakhloo; B B Lieber; S Rudin; M D Fronckowiak; R A Mericle; L N Hopkins
Journal:  J Neurosurg       Date:  1998-09       Impact factor: 5.115

10.  Experimental studies on new liquid embolization mixtures (histoacryl-lipiodol, histoacryl-panthopaque).

Authors:  F Stoesslein; G Ditscherlein; P A Romaniuk
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

View more
  2 in total

1.  Acute and chronic swine rete arteriovenous malformation models: hemodynamics and vascular remodeling.

Authors:  A K Wakhloo; B B Lieber; R Siekmann; D J Eber; M J Gounis
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

2.  Guidelines for the use of NBCA in vascular embolization devised by the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (CGJSIR), 2012 edition.

Authors:  Yoshito Takeuchi; Hiroyuki Morishita; Yozo Sato; Shingo Hamaguchi; Noriaki Sakamoto; Hiroyuki Tokue; Takafumi Yonemitsu; Kenji Murakami; Hiroyasu Fujiwara; Keitaro Sofue; Toshi Abe; Hideyuki Higashihara; Yasuo Nakajima; Morio Sato
Journal:  Jpn J Radiol       Date:  2014-06-03       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.